Compaction Properties of Particulate Proteins in Binary Powder Mixtures with Common Excipients

Author:

Holmfred Else1ORCID,Hirschberg Cosima1,Rantanen Jukka1ORCID

Affiliation:

1. Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark

Abstract

The increasing interest in protein- and peptide-based oral pharmaceuticals has culminated in the first protein-based products for oral delivery becoming commercially available. This study investigates the compaction properties of proteins in binary mixtures with common excipients up to 30% (w/w) of particulate protein. Two model proteins, lysozyme and bovine serum albumin, were compacted with either microcrystalline cellulose, spray-dried lactose monohydrate, or calcium hydrogen phosphate dihydrate at two different compaction pressures. Compared to the compacted pure materials, a significant increase in the tensile strength of the compacts was observed for the binary blends containing lysozyme together with the brittle excipients. This could be attributed to the increased bonding forces between the particles in the blend compared to the pure materials. The use of bovine serum albumin with a larger particle size resulted in a decrease in tensile strength for all the compacts. The change in the tensile strength with an increasing protein content was non-linear for both proteins. This work highlights the importance of considering the particulate properties of protein powders and that protein-based compacts can be designed with similar principles as small-molecules in terms of their mechanical tablet properties.

Funder

Innovation Fund Denmark

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference35 articles.

1. Current Status of Selected Oral Peptide Technologies in Advanced Preclinical Development and in Clinical Trials;Aguirre;Adv. Drug Deliv. Rev.,2016

2. Oral Delivery of Macromolecular Drugs: Where We Are after Almost 100 Years of Attempts;Moroz;Adv. Drug Deliv. Rev.,2016

3. Biopharmaceutical Benchmarks 2022;Walsh;Nat. Biotechnol.,2022

4. New Perspectives in Oral Peptide Delivery;Zizzari;Drug Discov. Today,2021

5. (2023, August 01). U.S. Food and Drug Administration FDA Approves First Oral GLP-1 Treatment for Type 2 Diabetes, Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3